Achieving 77% CGS Survival: Outcomes from Japan’s J-PVAD Study

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - AstraZenca; Bayer AG; Bristol-Myers Squibb; Daiichi-Sankyo/Elil Lilly and Company; Medtronic; Terumo Medical Corporation; Abbott Vascular